An insider is buying, but recent margin trends get poor marks.
The momentum favorite gets slammed on news of an FDA investigation.
The generic drugmaker shows new signs of life after months of struggle.
These two stocks have been consolidating and now appear ready to move in opposite directions.
ESRX still has a a historically low valuation.
The fear of 'dead money' has brought Quest back to an extremely low-risk entry point.
This is one of the few stocks still trading at a bargain valuation.
Action on the weekly chart of the managed-care provider appears constructive.
Cognizant and Valeant earnings rose in 2012 and see growth up 17% and 24% in 2013.
This stock is a steady climber, and it's at a glaring entry point.
I greatly appreciate the team for sharing my remembrance to Alan Abelson. It really did come from the heart.
I am becom...
I approach an earnings call as I do eating a lobster: tear it apart and leave nothing for the dogs in the back alley. ...
Real Money Pro Quick Links
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data
. Company fundamental data provided by Morningstar
. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.